However, overweight and obesity have emerged as an important issue in the CF population due to advancements in therapy and increased longevity, especially in recent years with the introduction of CF transmembrane conductance regulator (CFTR) modulator therapies [7,8,9,10]. The gene discussed is CFTR; the disease is obesity due to melanocortin 4 receptor deficiency.